195) tissue-engineered papilla (TEP), and to investigate the potential of a tissue-engineering method for soft-tissue augmentation, especially aesthetic improvement of BT, with mesenchymal stem cells (MSCs) as the isolated cells, platelet-rich plasma (PRP) as the growth factor and hyaluronic acid (HA) as the scaffold. |
PMID:23533047 DOI:10.1002/term.1737 |
2015 Journal of tissue engineering and regenerative medicine |
* Papilla regeneration by injectable stem cell therapy with regenerative medicine: long-term clinical prognosis. |
- Black triangle (BT), an open interproximal space between teeth, can cause aesthetic concerns, food impaction, phonetic difficulties and periodontitis. The aim of this study was to determine the possibility and long-term prognosis of novel papilla regeneration with regenerative medicine, i.e. tissue-engineered papilla (TEP), and to investigate the potential of a tissue-engineering method for soft-tissue augmentation, especially aesthetic improvement of BT, with mesenchymal stem cells (MSCs) as the isolated cells, platelet-rich plasma (PRP) as the growth factor and hyaluronic acid (HA) as the scaffold. The parameters were assessed from a clinical point of view by measuring the distance from the tip of the interproximal papilla to the base of the contact area in each study region. The mean volumes, operation times and follow-up periods of TEP were 1.32 ± 0.25 ml, 2.2 ± 1.62 times and 55.3 ± 17.7 months; the mean improved BT values were 2.55 ± 0.89 mm. An aesthetic improvement was achieved. TEP was able to provide aesthetic improvement of black triangle and predictable results, and could emerge as another novel option for periodontal regenerative therapy in periodontal diseases. |
(1)80 *null* | (15)5 as | (29)3 exposed | (43)2 expanded |
(2)47 and | (16)5 expressed | (30)3 have | (44)2 expressing |
(3)39 were | (17)5 of | (31)3 isolated | (45)2 had |
(4)26 in | (18)5 which | (32)3 showed | (46)2 labeled |
(5)12 (MSCs) | (19)4 (ASCs) | (33)3 we | (47)2 may |
(6)11 was | (20)4 has | (34)2 (ASCs), | (48)2 play |
(7)10 to | (21)4 is | (35)2 (BMSCs) | (49)2 present |
(8)9 with | (22)4 on | (36)2 (ECFCs) | (50)2 remains |
(9)7 are | (23)4 seeded | (37)2 (HSCs) | (51)2 such |
(10)6 can | (24)4 within | (38)2 after | (52)2 the |
(11)6 for | (25)3 (ASC) | (39)2 by | (53)2 via |
(12)6 from | (26)3 (ECs) | (40)2 caused | |
(13)6 or | (27)3 (HUVECs) | (41)2 cultured | |
(14)6 that | (28)3 (hMSCs) | (42)2 derived |
add keyword